Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -13.07 is 45% above its 5-year average of -23.67, near the high end of its 5-year range (-40.87–-9.41).
4.39% above its 12-month average of -13.67.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -2.32.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-13.07
EARNINGS PER SHARE (EPS) AVG TTM
-13.67
EARNINGS PER SHARE (EPS) AVG 3Y
-19.10
EARNINGS PER SHARE (EPS) AVG 5Y
-23.67
EARNINGS PER SHARE (EPS) AVG 10Y
-33.93
EARNINGS PER SHARE (EPS) AVG 15Y
-33.78
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+4.39%
CURRENT VS 3Y AVG
+31.58%
CURRENT VS 5Y AVG
+44.79%
CURRENT VS 10Y AVG
+61.48%
CURRENT VS 15Y AVG
+61.31%
CURRENT VS 20Y AVG
N/A
Karyopharm Therapeutics Inc.
Market Cap
$15.90M
Earnings Per Share (EPS)
-13.07
TTM Avg
-13.67
3Y Avg
-19.10
5Y Avg
-23.67
Market Cap
$15.72M
Earnings Per Share (EPS)
-0.78
TTM Avg
-8.29
3Y Avg
-9461.74
5Y Avg
-302593.36
Market Cap
$16.04M
Earnings Per Share (EPS)
-0.76
TTM Avg
-2.06
3Y Avg
-5.59
5Y Avg
-9.29
Market Cap
$15.42M
Earnings Per Share (EPS)
-0.77
TTM Avg
-1.25
3Y Avg
-1.82
5Y Avg
-1.86
Market Cap
$16.40M
Earnings Per Share (EPS)
-0.21
TTM Avg
-0.22
3Y Avg
-0.25
5Y Avg
-0.30
Market Cap
$16.75M
Earnings Per Share (EPS)
-3.73
TTM Avg
-46.49
3Y Avg
-194.14
5Y Avg
-195.03
Market Cap
$14.84M
Earnings Per Share (EPS)
-2.46
TTM Avg
-7.80
3Y Avg
-9.74
5Y Avg
-7.20
Market Cap
$16.76M
Earnings Per Share (EPS)
-4.76
TTM Avg
-17.55
3Y Avg
-9.83
5Y Avg
-7.78
Market Cap
$17.01M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.99
3Y Avg
-1.87
5Y Avg
-3.18
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | $15.90M | -13.07 | -13.67 | -19.10 | -23.67 |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.72M | -0.78 | -8.29 | -9461.74 | -302593.36 |
| BioCardia, Inc. (BCDA)vs › | $16.04M | -0.76 | -2.06 | -5.59 | -9.29 |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.42M | -0.77 | -1.25 | -1.82 | -1.86 |
| Dyadic International, Inc. (DYAI)vs › | $16.40M | -0.21 | -0.22 | -0.25 | -0.30 |
| Bionano Genomics, Inc. (BNGO)vs › | $16.75M | -3.73 | -46.49 | -194.14 | -195.03 |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.84M | -2.46 | -7.80 | -9.74 | -7.20 |
| Palatin Technologies, Inc. (PTN)vs › | $16.76M | -4.76 | -17.55 | -9.83 | -7.78 |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.01M | -0.48 | -0.99 | -1.87 | -3.18 |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.57M | N/A | -1.17 | -1.46 | -1.36 |
Trailing EPS (TTM)
$-13.07
Forward EPS (Est.)
$-4.84
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -17.93 |
| 2024-12-31 | -9.41 |
| 2023-12-31 | -18.79 |
| 2022-12-31 | -30.28 |
| 2021-12-31 | -24.75 |
| 2020-12-31 | -40.87 |
| 2019-12-31 | -48.32 |
| 2018-12-31 | -47.11 |
| 2017-12-31 | -42.15 |
| 2016-12-31 | -43.80 |
| 2015-12-31 | -49.80 |
| 2014-12-31 | -36.45 |
| 2013-12-31 | -83.85 |
| 2012-12-31 | -8.01 |
| 2011-12-31 | -5.20 |
